Additionally, genetic variances make it even more complicated to treat the condition with new treatments. Medics need to do more research on whether these new medications would be effective for the minority groups, explains Dr. MyMyBuu who works at the pulmonary medicine department in the department in Stanford university school of medicine in Palo Alto, Calif. He adds that they are trying to make advancements in the field to avoid any differences. The medics are also studying what causes these differences.

The lungs and the digestive system

This research will be of benefit to children who are born with cystic fibrosis and that they will be able to get treatment early enough too. The condition is passed from parents to their offspring. It affects the lungs and the digestive system. Most of the children who had this condition in California were born between the year 1991 and 2010. Out of all the patients used in the research, 28% of them suffered from Hispanic.

It was unfortunate that during the experiments done on them that 9 died which was slightly more than those who did not suffer from the condition. Chances of Hispanic patients dying were three times more than that of other patients. At first the medics thought that the patients who died was because of receiving medical care too late and some of them not being able to access health facilities, but this was later ruled out as some who were not affected by these factors died too.

Hispanic grew cysts fibrosis

One of the main difference between the groups experimented on was that those who were Hispanic grew cysts fibrosis difficulties sooner and they developed mutations that were not very common in the population. Medics are trying their best to understand these mutations and the most commonly observed mutations are being studied first then the less common ones will follow later.

Before the advancements in medicine, most of these patients died in their early years but these days they are able to survive longer. More than 50% of these patients are able to live up to 40 years and above. However, to date, those who have the rare mutations are still disadvantaged as their treatments are limited and in some cases unavailable.